Leerink Partners analyst Puneet Souda has maintained their neutral stance on HOLX stock, giving a Hold rating on May 2.
Puneet Souda has given his Hold rating due to a combination of factors affecting Hologic’s financial outlook. The company reported a slight decline in organic revenue growth, with particular strength in its molecular diagnostics segment being offset by ongoing challenges in its Breast Health division. Despite management’s efforts to address these issues, the broader business environment remains uncertain, particularly with emerging tariff and funding headwinds.
The impact of tariffs, especially on products imported from Costa Rica and exported to China, is expected to create significant cost pressures. This, combined with a softer capital expenditure environment, has led to a downward revision of the company’s earnings per share guidance. While Hologic’s molecular diagnostics franchise is strong, the overall uncertainties in the business landscape prompt a cautious stance, resulting in the Hold rating and a lowered price target of $60.
In another report released on May 2, UBS also maintained a Hold rating on the stock with a $65.00 price target.
HOLX’s price has also changed moderately for the past six months – from $82.330 to $57.280, which is a -30.43% drop .